Bradesco (NYSE: BBD) sets April 30 effectiveness for Odontoprev share merger

Rhea-AI Filing Summary

Banco Bradesco S.A. provides an update on its plan to consolidate the Bradesco Organization’s healthcare businesses into Odontoprev S.A.. Extraordinary general shareholders’ meetings of Odontoprev and Bradesco Gestão de Saúde S.A. approved the merger of BGS shares into Odontoprev and the contribution of Odontoprev’s operating assets and liabilities to Mediservice.

All conditions precedent in the merger protocol have been satisfied, including authorizations from Brazil’s National Supplementary Health Agency on March 30, 2026 for the share merger and April 2, 2026 for the asset contribution. Subject to board ratification, the merger of shares is expected to become effective on April 30, 2026, ahead of the end of the withdrawal-right period for dissenting shareholders. Bradesco states it will continue to inform shareholders of material developments.

Insights

Latin America banking & corporate actions analyst

Bradesco’s healthcare reorganization clears key Brazilian regulatory steps.

The update confirms that Odontoprev and Bradesco Gestão de Saúde shareholders approved the merger of BGS shares into Odontoprev plus an asset contribution to Mediservice. These moves centralize Bradesco’s healthcare activities around Odontoprev as the operating platform.

Importantly, the filing notes that all conditions precedent in the merger protocol are satisfied, including approvals from the National Supplementary Health Agency on March 30, 2026 and April 2, 2026. Remaining execution depends on board ratifications, with the merger of shares slated to be effective on April 30, 2026.

The transaction’s economic impact is not quantified here, but the structure suggests a corporate simplification and alignment of healthcare operations under Odontoprev. Subsequent company disclosures may add financial terms, integration updates, and any changes to Bradesco’s exposure to the healthcare segment.

Key Figures

ANS approval for Merger of Shares: March 30, 2026 ANS approval for Asset Contribution: April 2, 2026 Effective date of Merger of Shares: April 30, 2026 +1 more

4 metrics

ANS approval for Merger of Shares March 30, 2026 Authorization date for merger of Bradesco Gestão de Saúde shares into Odontoprev

ANS approval for Asset Contribution April 2, 2026 Authorization date for contribution of Odontoprev operating assets and liabilities to Mediservice

Effective date of Merger of Shares April 30, 2026 Planned effectiveness of BGS share merger into Odontoprev, subject to board ratification

Form type Form 6-K Foreign private issuer report under the Securities Exchange Act of 1934

Key Terms

Merger of Shares, Asset Contribution, National Supplementary Health Agency, withdrawal right, +1 more

5 terms

Merger of Shares financial

"the merger of shares of BGS by Odontoprev (“Merger of Shares”)"

Asset Contribution financial

"the contribution of operating assets and liabilities of Odontoprev to Mediservice"

National Supplementary Health Agency regulatory

"including the authorizations by the National Supplementary Health Agency (“ANS“)"

withdrawal right regulatory

"the period for ... the exercise of the withdrawal right by its dissenting shareholders"

Extraordinary General Shareholders' Meetings financial

"the Extraordinary General Shareholders' Meetings of Odontoprev and Bradesco Gestão de Saúde S.A."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 04/06/2026 - 06:07 PM Learn about SEC filing dates

FAQ

What corporate transaction did Banco Bradesco (BBD) update involving Odontoprev?

Banco Bradesco updated its plan to consolidate Bradesco Organization healthcare businesses into Odontoprev. Shareholders of Odontoprev and Bradesco Gestão de Saúde approved the merger of BGS shares into Odontoprev and the contribution of Odontoprev’s operating assets and liabilities to Mediservice.

Which regulatory approvals has the Bradesco–Odontoprev healthcare reorganization received?

The reorganization obtained approvals from Brazil’s National Supplementary Health Agency. Authorization for the merger of Bradesco Gestão de Saúde shares into Odontoprev came on March 30, 2026, and approval for the asset contribution to Mediservice followed on April 2, 2026.

When is the merger of BGS shares into Odontoprev expected to become effective?

Subject to ratification by the boards of Odontoprev and Bradesco Gestão de Saúde, the merger of shares is expected to become effective on April 30, 2026. This planned effectiveness date comes before the end of the withdrawal-right period for Odontoprev’s dissenting shareholders.

How does the Bradesco healthcare consolidation affect Odontoprev’s operations?

The consolidation moves Odontoprev’s operating assets and liabilities into Mediservice while Odontoprev absorbs Bradesco Gestão de Saúde shares. This structure aims to centralize Bradesco Organization healthcare activities around Odontoprev and its subsidiaries, potentially simplifying governance and operational alignment.

Will Banco Bradesco (BBD) continue to report developments on the Odontoprev transaction?

Banco Bradesco states it will keep shareholders and the market informed of any material developments related to the Odontoprev transaction. Future communications are expected to follow applicable regulations and may provide additional detail on execution steps and any resulting effects.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number 1-15250

BANCO BRADESCO S.A. 

(Exact name of registrant as specified in its charter)

BANK BRADESCO

(Translation of Registrant's name into English)

Cidade de Deus, s/n, Vila Yara
06029-900 - Osasco - SP
Federative Republic of Brazil

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F ___X___ Form 40-F _______

 Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  

Yes _______ No ___X____

 .

 

Update on the Corporate Reorganization to Consolidate the Healthcare Businesses of Bradesco Organization in Odontoprev

Banco Bradesco S.A. (“Bradesco”), in continuance to the Material Fact disclosed on February 27, 2026 and the Notice to the Market disclosed on March 6, 2026, related to the consolidation of the healthcare businesses of the Bradesco Organization in Odontoprev S.A. (“Odontoprev” and “Transaction”), hereby informs its shareholders and the market in general that, on the date hereof, the Extraordinary General Shareholders' Meetings of Odontoprev and Bradesco Gestão de Saúde S.A. (“BGS”) were held, at which the following were approved, among other related matters: the merger of shares of BGS by Odontoprev (“Merger of Shares”) and the contribution of operating assets and liabilities of Odontoprev to Mediservice Operadora de Planos de Saúde S.A. (“Asset Contribution” and “Mediservice”).

It is also highlighted that all conditions precedent set forth in the “Protocol and Justification for the Merger of Shares of Bradesco Gestão de Saúde S.A. by Odontoprev S.A.”, as amended and consolidated, have been duly satisfied, including the authorizations by the National Supplementary Health Agency (“ANS“) on March 30, 2026, for the implementation of the Merger of Shares, and on April 2, 2026, for the consummation of the Asset Contribution.

Subject to ratification by the Boards of Directors of Odontoprev and BGS, the Merger of Shares shall become effective on April 30, 2026, therefore prior to the expiration of the period for (and with the waiver by the Board of Directors of Odontoprev of the reconsideration of the Transaction by reason of) the exercise of the withdrawal right by its dissenting shareholders.

Without prejudice to further details contained in the disclosures made by Odontoprev, Bradesco will keep its shareholders and the market in general informed of any material developments related to the Transaction, pursuant to the applicable regulations.

Cidade de Deus, Osasco, SP, April 6, 2026.

Banco Bradesco S.A.

André Costa Carvalho
Investor Relations Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 6, 2026

BANCO BRADESCO S.A.
By:		/S/André Costa Carvalho
		André Costa Carvalho Investor Relations Officer

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on management's current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words "anticipates", "believes", "estimates", "expects", "plans" and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.